SPARCL1 and colorectal carcinoma: Further, CDH2 and SPARCL1 were associated with poor prognosis in CRC, suggesting that both may represent potential genetic biomarkers for poor prognosis in CRC, and may provide potential value for CRC treatment in the future (Figure 11).